Berkeley Heights, NJ, September 9, 2003
Audio of the meeting can be accessed as follows:
U.S./Canada: Dial (877) 634-8606, reference code: 2741957.
International: Dial (706) 679-3140, reference code: 2741957.
A replay will be available two hours after the completion of the
presentation and archived through Friday, October 10, 2003 for 30
days, accessible as follows:
U.S./Canada: Dial (800) 642-1687, enter 2741957 for conference ID.
International: Dial (706) 645-9291, enter 2741957 for conference
ID.
The audio webcast will be available at the company's Investor
Relations website at:
http://www.genta.com/genta/InvestorRelation/events.html
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on DNA/RNA-based medicines and small molecules. Genasense
TM
(oblimersen sodium) is the Company's lead compound from its DNA/RNA
Medicines program and is currently undergoing late-stage, Phase 3
clinical testing. The leading drug in Genta's small molecule
program is Ganite
TM
(gallium nitrate injection), which the Company intends to market
for the treatment of cancer-related hypercalcemia that is resistant
to hydration. For more information about Genta, please visit our
website at:
http://www.genta.com/
.
This press release and the conference call and webcast to
follow contain forward-looking statements with respect to
business conducted by Genta Incorporated. By their nature,
forward-looking statements and forecasts involve risks and
uncertainties because they relate to events and depend on
circumstances that will occur in the future. There are a number
of factors that could cause actual results and developments to
differ materially. For a discussion of those risks and
uncertainties, please see the Company's Annual
Report/Form 10-K
for 2002.
SOURCE: Genta Incorporated
